The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First results of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma.
 
Linde Kehmann
Employment - SERVIER
 
Maria Gonzalez-Carmona
No Relationships to Disclose
 
Marie-Luise Berres
No Relationships to Disclose
 
Dominik Modest
Honoraria - 21up; Amgen; AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Cor2Ed; GlaxoSmithKline; IKF Klinische Krebsforschung; Lilly; Merck; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; Rottapharm Biotech; Seagen; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Cor2Ed; GlaxoSmithKline; Incyte; Lilly; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; SERVIER; Takeda
Research Funding - Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER
 
Raphael Mohr
No Relationships to Disclose
 
Alexander Wree
No Relationships to Disclose
 
Marino Venerito
No Relationships to Disclose
 
Christian Strassburg
No Relationships to Disclose
 
Verena Keitel
No Relationships to Disclose
 
Dirk Waldschmidt
No Relationships to Disclose
 
Sven Loosen
No Relationships to Disclose
 
Tom Ludde
No Relationships to Disclose
 
Christoph Roderburg
Research Funding - SERVIER (Inst)